SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells

  • Wang, Hong-Ling (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Lu, Ren-Quan (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Xie, Su-Hong (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Zheng, Hui (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Wen, Xue-Mei (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Gao, Xiang (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center) ;
  • Guo, Lin (Department of Clinical Laboratory, Fudan University Shanghai Cancer Center)
  • Published : 2015.04.29


Background: Sirtuin7 (SIRT7) is a type of nicotinamide adenine dinucleotide oxidized form (NAD+)-dependent deacetylase and the least understood member of the sirtuins family; it is implicated in various processes, such as aging, DNA damage repair and cell signaling transduction. There is some evidence that SIRT7 may function as a tumor trigger for human malignancy. Here, we aimed to explore the biological function of SIRT7 in ovarian carcinoma cells and its potential mechanism. Materials and Methods: Expression of SIRT7 in ovarian cancer cell lines was detected by western blotting. Transduced cell lines with SIRT7 knockdown or overexpression were constructed. Cell viability, cologenic, apoptosis-associated and motility assays were performed to elucidate the biological function of SIRT7 in ovarian cancer cells. Results: SIRT7 demonstrated a higher level in ovarian cancer cell lines compared with normal cells. On the one hand, down-regulation of SIRT7 significantly reduced ovarian cancer cell growth, repressed colony formation and increased cancer cell apoptosis; on the other hand, up-regulation promoted the migration of cancer cells. Additionally, repression of SIRT7 also induced change in apoptosis-related molecules and subunits of the NF-${\kappa}B$ family. Conclusions: In the present study, our data indicated that SIRT7 might play a role of oncogene in ovarian malignancy and be a potential therapeutic target.


SIRT7;ovarian cancer cells;deacetylase;NF-${\kappa}B$


Supported by : Science and Technology Commission of Shanghai Municipality


  1. Alvero AB (2010). Recent insights into the role of NF-kappaB in ovarian carcinogenesis. Genome Med, 2, 56.
  2. Ashraf N, Zino S, Macintyre A, et al (2006). Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer, 95, 1056-61.
  3. Barber MF, Michishita-Kioi E, Xi Y, et al (2012). SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature, 487, 114-8.
  4. Blander G, Guarente L (2004). The Sir2 family of protein deacetylases. Annu Rev Biochem, 73, 417-35.
  5. Bosch-Presegue L, Vaquero A (2011). The dual role of sirtuins in cancer. Genes Cancer, 2, 648-662.
  6. Chen WT, Gao X, Han XD, et al (2014). HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 101-5.
  7. Ford E, Voit R, Liszt G, et al (2006). Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev, 20, 1075-80.
  8. Han Y, Liu Y, Zhang H, et al (2013). Hsa-miR-125b suppresses bladder cancer development by down-regulating oncogene SIRT7 and oncogenic long noncoding RNA MALAT1. FEBS Lett, 587, 3875-82.
  9. Jemal A, Murray T, Samuels A, et al (2003). Cancer statistics, 2003. CA Cancer J Clin, 53, 5-26.
  10. Kim JK, Noh JH, Jung KH, et al (2013). Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology, 57, 1055-67.
  11. Lai CC, Lin PM, Lin SF, et al (2013). Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol, 34, 1847-54.
  12. Lavu S, Boss O, Elliott PJ, et al (2008). Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov, 7, 841-53.
  13. North BJ, Verdin E (2004). Sirtuins: Sir2-related NADdependent protein deacetylases. Genome Biol, 5, 224.
  14. Shin J, He M, Liu Y, et al (2013). SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease. Cell Rep, 5, 654-65.
  15. Tsai YC, Greco TM, Boonmee A, et al (2012). Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription. Mol Cell Proteomics, 11, 60-76.
  16. Vakhrusheva O, Smolka C, Gajawada P, et al (2008). Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res, 102, 703-10.
  17. Yu H, Ye W, Wu J, et al (2014). Overexpression of sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. Clin Cancer Res, 20, 3434-45.

Cited by

  1. MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells vol.36, pp.5, 2016,
  2. Sirtuins Expression and Their Role in Retinal Diseases vol.2017, pp.1942-0994, 2017,
  3. Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer vol.21, pp.10, 2017,
  4. The seven faces of SIRT7 vol.8, pp.2, 2017,
  5. MicroRNA-3666 inhibits breast cancer cell proliferation by targeting sirtuin 7 vol.16, pp.6, 2017,
  6. Genetic variants in the histone methylation and acetylation pathway and their risks in eight types of cancers vol.19, pp.2, 2018,
  7. Advances in Cellular Characterization of the Sirtuin Isoform, SIRT7 vol.9, pp.1664-2392, 2018,
  8. Sirtuin 7 Deficiency Ameliorates Cisplatin-induced Acute Kidney Injury Through Regulation of the Inflammatory Response vol.8, pp.1, 2018,
  9. Dual Tumor Suppressor and Tumor Promoter Action of Sirtuins in Determining Malignant Phenotype vol.10, pp.1663-9812, 2019,